Acta Pharmaceutica Sinica B, 2024, ISSN 2211-3835
The study introduces a nano-modulator that targets the damaged blood-brain barrier in Alzheimer’s disease. This modulator releases therapeutic agents that reduce amyloid-beta load, alleviate neuroinflammation, and restore neurovascular unit function, showing potential for Alzheimer’s treatment.
Elsevier,
Pharmacological Research, Volume 203, May 2024
This article explores the link between alcohol consumption and Alzheimer’s disease (AD), focusing on how serotonergic dysfunction may mediate this relationship. It highlights the roles of neuroinflammation and proteostasis in this process
Elsevier,
Journal of Ginseng Research, Volume 48, May 2024
This review describes recent clinical contributors to ginseng components in clinical tests and introduces emerging evidence that ginseng components could be novel candidates for cognitive improvement in older individuals, as ginseng components improve SMI cognition and exhibits add-on effects when co-administered with early AD dementia drugs. The mechanism behind the beneficial effects of ginseng components and how it improves cognition are presented.
Elsevier,
Behavioural Brain Research, Volume 465, 8 May 2024
This article discusses age-related changes in species-typical behaviors, such as exploration and grooming, in female 5xFAD mouse model of Alzheimer's disease, suggesting that these behaviors may serve as valuable indicators for modeling the decline in activities of daily living observed in AD patients and assessing the efficacy of potential therapeutics.
Elsevier,
Neuroscience, Volume 546, 14 May 2024
This study investigated VGLUT1 and VGLUT2 expression in the medial temporal lobe and superior temporal gyrus in Alzheimer's disease (AD). The findings reveal region-specific vulnerabilities, with significantly lower VGLUT1 in the dentate gyrus and VGLUT2 in the subiculum and superior temporal gyrus, suggesting potential therapeutic targets that require further exploration.
